Retatrutide's Glucagon Receptor: Does It Really Kick In at 4mg?

Do you really need to be at four milligrams of retitrutide per week before the glucagon receptor actually starts working? Well, a lot of folks have been asking me about this, so let me break down what the data actually shows.

Before we get into the dose question, it helps to have the whole chain in front of you, because the answer depends on how each piece hands off to the next.

A drug molecule circulates in your blood at some concentration. It bumps into receptors on the surface of cells. When enough of those receptors are occupied and activated, the cell changes what it is doing. That change is the effect you feel and the effect that shows up in a blood test or on a body composition scan.

So there are four separate things stacked on top of each other: your dose, your blood concentration, how much receptor activity that concentration produces, and how big the downstream effect has to get before anyone can measure it.

Most of the confusion around the four milligram number comes from collapsing those four things into one.

Retitrutide activates three receptors, GLP-1, GIP, and glucagon. That is what I have seen described consistently in the reporting on this compound, though I cannot point you to a study I have in front of me that lays out all three side by side with clean numbers.

Each receptor has its own sensitivity to the drug, meaning each one needs a different amount of drug sitting in your bloodstream to produce the same fraction of its maximum response. And the way researchers measure that is with something called EC50, which is just the concentration of a specific drug needed to produce 50% of the maximum possible response at a specific receptor.

A low EC50 means the receptor is easy to activate, because it only takes a small concentration to get halfway to maximum. A high EC50 means the receptor is stubborn, and you need more drug in circulation to get that same halfway point.

For retitrutide, the ranking that gets passed around is that GIP is the most sensitive, GLP-1 sits in the middle, and glucagon is the least sensitive of the three. From what I have seen that ordering holds up in practice and matches how people respond as they climb doses, but the research hasn't given us a single clean public table I can hand you with all three EC50 values in it, so treat the ranking as a working model rather than a settled number.

What the ranking does explain is the pattern everyone notices. As you increase the dose, you're progressively recruiting more and more glucagon receptor activity along a gradual curve.

And that word gradual is very key here.

Receptor activation does not work like a light switch where nothing is happening and then suddenly everything turns on at a specific dose, and that holds true well beyond retitrutide since it is simply how receptors behave in general, a pattern that has been measured directly at the level of individual ion channels, where increasing agonist concentration increases the number of channels that open rather than flipping any single channel from off to on (Chabala 1986).

If you search sigmoidal dose response curve, you can actually see what this looks like. It's an S-shaped curve where the response starts small at low concentration, ramps up through the middle, and then levels off at the top.

Think of it like rain hitting a windshield, where a single drop landing on the glass does not send the wipers into motion, and neither does a second or a third, at least not in a way you would notice or act on. But somewhere around a certain rate of rainfall the windshield is wet enough that you finally reach over and turn the wipers on, and it feels like a threshold got crossed even though every drop before that moment was landing and contributing its share. The glass itself, sitting there collecting each drop without visibly changing, works the same way a receptor does, quietly accumulating input long before anything obvious happens. What changes is only your attention, the moment you finally notice and reach for the switch.

There is another piece of this that matters. A drug does not have to fully activate a receptor to be doing something to it. Compounds can be partial agonists, where they occupy the receptor and produce a submaximal response no matter how much you give, and buprenorphine is the textbook case of a drug whose effect at one receptor plateaus while its effect at another keeps changing (Cowan 2003).

Beyond that, receptors influence one another in ways that complicate any attempt to study them in isolation, since activating one receptor can change how a completely separate receptor responds, a phenomenon shown directly in hippocampal tissue where adenosine receptor activation shifts the behavior of a separate dinucleotide receptor (Díaz-Hernández 2002).

So with three receptors being hit at once, at three different sensitivities, the total picture is not three independent dials. It is three overlapping curves, and the shape of the combined effect depends on where you sit on all three at the same time.

So where did this four milligram reference come from? Well, in the phase two liver fat sub-study, researchers measured something called beta-hydroxybutyrate, which is a molecule your liver produces when it's actively burning stored fat for fuel.

It belongs to a class of molecules called ketone bodies, and your liver makes it when fatty acids are being broken down faster than they are being stored, so its level in blood is a reasonably direct readout of whether fat oxidation in the liver has gone up.

The number that gets quoted is that this biomarker rose two to three times above baseline at doses of four milligrams and higher. I have seen that figure repeated widely, and it lines up with what the glucagon receptor is expected to do, but there is no study summary in my hands that I can point you to with those exact values, so I am telling you that as the reported figure rather than as something I have verified line by line.

And that also lined up with the biggest jump in actual fat loss measured by DEXA scans in the clinical trials. Same caveat there, said plainly: the research hasn't been laid out for me in a form where I can show you the dose by dose DEXA breakdown, so that one is also reported rather than confirmed.

So four milligrams is where the glucagon-driven effects became clearly measurable in blood work and clearly visible in body composition data.

But that's different from saying the receptor was off below that dose.

At two milligrams the receptor was being occupied and it was producing output. That output just was not large enough to separate itself from normal variation between people in a study of that size. Every biomarker has noise in it, and a small real effect sitting inside a large noise band does not become a statistically significant finding.

Absence of a detectable signal is a statement about the measurement, not about the receptor.

What follows from that matters for anyone actually deciding how to dose. If you believe the glucagon receptor is off below four milligrams, then every dose under that looks like wasted time, and the only logical move is to climb as fast as your side effects allow. If you understand that activation scales gradually, then the lower doses are already doing part of the work, and you titrate based on what your body is telling you rather than racing to cross an imaginary line.

Now here's the thing worth acknowledging. Saying four milligrams is where the glucagon kicks in is a simplification.

And it's actually a pretty useful one because when you're trying to give someone practical guidance, a clean reference point that they can act on is much more valuable than, well, it depends on your individual dose response curve. It doesn't do you any good being the smartest guy in the room if nobody can understand what you're saying.

But it's also important to understand that that simplification can become a problem when someone presents it as a hard fact rather than a practical guideline.

Two different mistakes tend to grow out of the same misunderstanding. Someone sitting at three milligrams with good appetite control, steady weight loss and manageable side effects decides they are accomplishing nothing and pushes to four, gets nauseated, and stalls out entirely. Or someone reaches four milligrams, sees the number as a finish line, and stops paying attention to their own response because they assume the box is checked.

Research: Chabala 1986 (J Physiol), Cowan 2003 (Int J Clin Pract Suppl), Díaz-Hernández 2002 (J Pharmacol Exp Ther).

References:

Cowan A. Buprenorphine: new pharmacological aspects. Int J Clin Pract Suppl. 2003. https://pubmed.ncbi.nlm.nih.gov/12665117/

Chabala LD, Gurney AM, Lester HA. Dose-response of acetylcholine receptor channels opened by a flash-activated agonist in voltage-clamped rat myoballs. J Physiol. 1986. https://pubmed.ncbi.nlm.nih.gov/2422352/

Díaz-Hernández M, Pereira MF, Pintor J et al.. Modulation of the rat hippocampal dinucleotide receptor by adenosine receptor activation. J Pharmacol Exp Ther. 2002. https://pubmed.ncbi.nlm.nih.gov/11961042/